Amylyx Pharmaceuticals, Inc. (AMLX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -162.10M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 92.45M USD | Research and Development Expense |
| Selling, general and administration | 69.66M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-162.10M | (m) | (m) | $92.45M | $69.66M | (m) |
| 2026-03-31 | $-159.27M | (m) | (m) | $95.89M | $63.37M | (m) |
| 2025-12-31 | $-153.29M | $0.00 | $0.00 | $90.40M | $62.89M | (m) |
| 2025-09-30 | $-157.34M | $-665.00K | $0.00 | $92.08M | $64.59M | 23660.15% |
| 2025-06-30 | $-196.97M | $-249.00K | $0.00 | $93.47M | $66.25M | 79106.43% |
| 2025-03-31 | $-230.40M | $-1.27M | $8.00K | $89.59M | $72.26M | 18113.52% |
| 2024-12-31 | $-314.73M | $87.37M | $5.95M | $104.08M | $114.33M | -360.22% |
| 2024-09-30 | $-272.14M | $196.49M | $15.31M | $126.11M | $149.47M | -138.51% |
| 2024-06-30 | $-177.76M | $298.76M | $20.53M | $134.91M | $180.37M | -59.50% |
| 2024-03-31 | $-81.28M | $398.00M | $26.10M | $140.60M | $202.11M | -20.42% |
| 2023-12-31 | $38.80M | $380.79M | $25.44M | $128.19M | $188.36M | 10.19% |
| 2023-09-30 | $-7.72M | $294.22M | $18.90M | $106.09M | $176.96M | -2.63% |
| 2023-06-30 | $-81.13M | $191.87M | $13.86M | $100.96M | $158.18M | -42.28% |
| 2023-03-31 | $-155.58M | (m) | (m) | $96.18M | $144.78M | (m) |
| 2022-12-31 | $-201.34M | $22.23M | $2.99M | $93.45M | $127.13M | -905.72% |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-82.69M | $285.00K | (m) | $44.04M | $38.93M | -29013.33% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |